9 results about "Abacavir" patented technology

The invention discloses a medicine composition containing homoharringtonine and application of the medicine composition in preparation of an anti-HIV (human immunodeficiency virus) medicine. The medicine composition is composed of the homoharringtonine and a nucleoside reverse transcriptase inhibitor or a non-nucleoside reverse transcriptase inhibitor, the nucleoside reverse transcriptase inhibitor is selected from one of the compounds of zidovudine, lamivudine and abacavir, and the non-nucleoside reverse transcriptase inhibitor is selected from one of the compounds of nevirapine, efavirenz and rilpivirine. The pharmaceutical composition has a remarkable synergistic effect on treatment of HIV, the curative effect of the medicine is improved, the dosage of a single medicine is reduced, the toxic and side effects are reduced, the generation of viruses can be remarkably inhibited by combined medication, a very remarkable antiviral effect is generated, and the treatment current situation of HIV-1, especially middle and advanced AIDS, is improved.

The application discloses a preparation method of an abacavir metabolite, and belongs to the field of drug metabolite synthesis. The whole process is reasonable in design, strong in operability, and has high implementation value and social and economic benefits. The method uses compound I as a starting material, and synthesizes the abacavir metabolite through two-step reactions. The optimal synthesis step and reaction condition are screened through experiments. The abacavir metabolite synthesized by the method has a liquid-phase purity of 98.2% or above and a chiral purity of 99.9% or above, provides a test sample for abacavir research, and has important research reference value in clinical pharmacokinetic research and new drug research and development.

The invention discloses a preparation method of abacavir impurities, and particularly, the abacavir impurities are prepared by taking 2-azabicyclo [2, 2, 1] hept-5-ene-3-ketone as a raw material through ring opening, resolution, resolution, upper protection, reduction, deprotection, condensation, ring closing and condensation. The invention also discloses application of the abacavir impurity prepared by the preparation method in detection and / or control of abacavir quality, a new thought is provided for synthesis of the abacavir impurity, the initial raw materials of the synthesis method are easy to obtain, the reaction conditions of the synthesis route are mild, the reaction operation is safe, and the method is suitable for industrial production. And the yield and the purity are good, so that the preparation requirements of the impurity can be met, and the abacavir impurity is of great significance to research of abacavir impurities.

The present invention discloses a pharmaceutical composition containing homoharringtonine and its application in the preparation of anti-HIV viral drugs. The pharmaceutical composition is composed of homoharringtonine and a nucleoside reverse transcriptase inhibitor or a non-nucleoside reverse transcriptase inhibitor. The nucleoside reverse transcriptase inhibitor is selected from one of the compounds zidovudine, lamivudine, and abacavir, and the non-nucleoside reverse transcriptase inhibitor is selected from one of the compounds nevirapine, efavirenz, and rilpivirine. The pharmaceutical composition has a significant synergistic effect in treating HIV, improves the efficacy of the drug, reduces the dosage of a single drug, reduces toxic side effects, and can significantly inhibit the production of viruses in combination, producing a very significant antiviral effect, and improving the current status of the treatment of HIV-1, especially middle and late stage AIDS.

The invention relates to application of abacavir in preparation of a medicine for treating rheumatoid arthritis, and belongs to the technical field of biological medicine. The abacavir is found to be capable of relieving related symptoms of rheumatoid arthritis for the first time, and particularly, abacavir is proved to be capable of inhibiting joint swelling and bone erosion of mice and relieving pathological phenotypes in a collagen-induced arthritis mouse model; meanwhile, in a peripheral blood mononuclear cell (PBMCs) sample of a patient with rheumatoid arthritis, abacavir is found to be capable of reducing expression of interferon stimulated gene (ISGs) family related genes, so that abacavir can be used as a novel therapeutic drug for rheumatoid arthritis. In conclusion, abacavir can be used as a medicine for treating rheumatoid arthritis and has very high clinical application value.

Provided is a method of treating a subject with an α-synucleinopathy neurodegenerative disorder, the method comprising administering one or more therapeutic(s) to the subject, a method of treating a subject with a high risk of developing an α-synucleinopathy neurodegenerative disorder, the method comprising administering one or more therapeutic(s) to the subject, wherein the one or more therapeutic(s) is or comprise rifabutin, one or more nucleoside analog reverse transcriptase inhibitor(s), optionally selected from lamivudine, emtricitabine, tenofovir disoproxil funiarate, tenofovir alafenamide, abacavir, zidovudine, didanosine, and / or stavudine, losartan, or a combination thereof.

The application discloses an abacavir degrading bacterium. The degrading bacterium is obtained from activated sludge in an aerobic tank of a sewage treatment plant in Guangzhou, Guangdong, and is obtained through artificial domestication culture and separation and purification. The name of the bacterium is Pseudomonas sp. abacavir-1, and the bacterium is preserved in the Guangdong Microbial Culture Collection Center of the Guangdong Institute of Microbiology, located at No. 59, Building 5, Guangzhou Martyrs' Road, Guangzhou, on September 23, 2022, and the preservation number is GDMCC NO: 62829. The strain of the application has the ability to degrade single abacavir under oligotrophic conditions, can be used for degrading abacavir in the environment or a sewage treatment plant, and provides a new germplasm resource for abacavir treatment.

The application relates to application of abacavir in preparation of a drug for treating rheumatoid arthritis, and belongs to the technical field of biological medicine. It is found for the first time that abacavir can relieve the related symptoms of rheumatoid arthritis, and specifically, it is proved in a collagen-induced arthritis mouse model that abacavir can inhibit joint swelling and bone erosion of the mouse, and relieve the pathological phenotype; meanwhile, it is found in peripheral blood mononuclear cell (PBMCs) samples of rheumatoid arthritis patients that the use of abacavir can reduce the expression of interferon stimulated gene (ISG) family related genes, which indicates that the abacavir can be used as a new type of drug for treating rheumatoid arthritis. In summary, the abacavir can be used as a drug for treating rheumatoid arthritis, and has high clinical application value.

The invention provides a double-layer tablet and a preparation method thereof. The double-layer tablet comprises a first layer and a second layer, the first layer is prepared from 50 parts of dotegravir or pharmaceutically acceptable salt (based on dotegravir), 30 to 60 parts of modified mesoporous silicon dioxide, 60 to 80 parts of first filling agent, 30 to 50 parts of first disintegrating agent, 300 parts of lamivudine, 80 to 120 parts of second filling agent, 20 to 30 parts of second flow aid, 400 to 700 parts of third filling agent, 100 to 150 parts of third disintegrating agent, 150 to 200 parts of first sweetening agent and 40 to 60 parts of third flow aid; and the second layer comprises 600 parts of abacavir or pharmaceutically acceptable salt (based on abacavir), 950-1200 parts of a fourth filling agent, 120-150 parts of a fourth disintegrating agent, 30-50 parts of a fourth flow aid and 30-40 parts of a second sweetening agent. The first layer is prepared by adopting a direct powder compression method, and then the raw materials of the second layer are mixed and compressed onto the first layer to obtain the double-layer tablet. The operation is simplified, the production efficiency of the medicinal preparation is improved, and industrial large-scale production and manufacturing are facilitated.